Giuseppe C.M. Graziosi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Giuseppe C.M. Graziosi has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
H.W. Bruinse
3 shared publicationsB.W. Mol
2 shared publicationsHein W. Bruinse
Department of Obstetrics and Gynecology, University Medical Centre, Utrecht, The Netherlands
2 shared publicationsA.P. Drogtrop
1 shared publication- Andreas L. Thurkow
Department of Obstetrics and Gynaecology, Sint Lucas Andreas Hospital, Amsterdam, the Netherlands
1 shared publication - Annemieke Hoek
10Department of Obstetrics and Gynaecology, University Medical Centre Groningen, Groningen, The Netherlands
1 shared publication
Latest Publications
- 1 February 2017
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 72 (2) , 89-90
Word Catheter and Marsupialisation in Women With a Cyst or Abscess of the Bartholin Gland (WoMan-Trial): A Randomised Clinical Trial
(ed from BJOG 2017;124:243–249) There is a 2% lifetime risk among women of developing a cyst or abscess of the Bartholin gland. These usually occur during reproductive ages; both can limit activity, and an abscess can also cause extreme pain.
- 1 February 2017
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 72 (2) , 89-90
Word Catheter and Marsupialisation in Women With a Cyst or Abscess of the Bartholin Gland (WoMan-Trial): A Randomised Clinical Trial
(ed from BJOG 2017;124:243–249) There is a 2% lifetime risk among women of developing a cyst or abscess of the Bartholin gland. These usually occur during reproductive ages; both can limit activity, and an abscess can also cause extreme pain.
- Open Access
- 26 June 2008
- Published by Springer Nature in BMC Women's Health
- Vol. 8 (1) , 11
The ESEP study: Salpingostomy versus salpingectomy for tubal ectopic pregnancy; The impact on future fertility: A randomised controlled trial
For most tubal ectopic pregnancies (EP) surgery is the treatment of first choice. Whether surgical treatment should be performed conservatively (salpingostomy) or radically (salpingectomy) in women wishing to preserve their reproductive capacity, is subject to debate. Salpingostomy preserves the tube, but bears the risks of both persistent trophoblast and repeat ipsilateral tubal EP. Salpingectomy, avoids these risks, but leaves only one tube for reproductive capacity. This study aims to reveal the trade-off between both surgical options: whether the potential advantage of salpingostomy, i.e. a better fertility prognosis as compared to salpingectomy, outweighs the potential disadvantages, i.e. persistent trophoblast and an increased risk for a repeat EP.
- 26 June 2008
- Published by Springer Nature in BMC Women's Health
- Vol. 8 (1) , 11
Open AccessThe ESEP study: Salpingostomy versus salpingectomy for tubal ectopic pregnancy; The impact on future fertility: A randomised controlled trial
For most tubal ectopic pregnancies (EP) surgery is the treatment of first choice. Whether surgical treatment should be performed conservatively (salpingostomy) or radically (salpingectomy) in women wishing to preserve their reproductive capacity, is subject to debate. Salpingostomy preserves the tube, but bears the risks of both persistent trophoblast and repeat ipsilateral tubal EP. Salpingectomy, avoids these risks, but leaves only one tube for reproductive capacity. This study aims to reveal the trade-off between both surgical options: whether the potential advantage of salpingostomy, i.e. a better fertility prognosis as compared to salpingectomy, outweighs the potential disadvantages, i.e. persistent trophoblast and an increased risk for a repeat EP.
- 1 February 2006
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 124 (2) , 184-186
Women's preferences for misoprostol in case of early pregnancy failure
- 1 February 2006
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 124 (2) , 184-186
Women's preferences for misoprostol in case of early pregnancy failure
- Open Access
- 1 June 2005
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 20 (6) , 1749-1750
Fertility outcome after a randomized trial comparing curettage with misoprostol for treatment of early pregnancy failure
1St Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, 2University Medical Centre, Heidelberglaan 100, 3584 CX Utrecht, 3St Elisabeth Hospital, Hilvarenbee
- 1 June 2005
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 20 (6) , 1749-1750
Open AccessFertility outcome after a randomized trial comparing curettage with misoprostol for treatment of early pregnancy failure
1St Antonius Hospital, Koekoekslaan 1, 3435 CM, Nieuwegein, 2University Medical Centre, Heidelberglaan 100, 3584 CX Utrecht, 3St Elisabeth Hospital, Hilvarenbee
- Open Access
- 14 April 2005
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 20 (8) , 2340-2347
Misoprostol versus curettage in women with early pregnancy failure: impact on women's health-related quality of life. A randomized controlled trial
BACKGROUND: We aimed to compare patients' health-related quality of life after a misoprostol strategy to a curettage in women with early pregnancy failure after failed expectant management. METHODS: A multicentre randomized clinical trial was performed in The Netherlands. In all, 154 women with early pregnancy failure confirmed at ultrasonography who had been managed expectantly unsuccessfully for ≥1 week were randomly assigned to undergo either treatment with misoprostol (n=79) or curettage (n=75). The main outcome measures were health-related quality of life and satisfaction with treatment. RESULTS: In the misoprostol strategy 47% of the women needed additional curettage, as compared to 4% after curettage. In both groups, health-related quality of life was impaired most severely 2 days after treatment. In the misoprostol group, health-related quality of life was more severely impaired; after 2 days this was due to more pain and after 2 and 6 weeks this was due to a worse general health perception. Health-related quality of life was temporarily significantly more impaired in women in whom misoprostol failed as compared to women in whom misoprostol treatment was successful. In both treatment groups, an equal percentage of women (58%) would choose the same treatment in the future. In women treated with misoprostol, however, this choice depended on the initial success of misoprostol: in cases where misoprostol had caused complete evacuation, 76% of the women would opt for the same treatment, whereas only 38% of women who needed curettage after unsuccessful misoprostol would do so (P<0.01). CONCLUSION: Our study shows that, although both the misoprostol strategy and the curettage strategy resulted in complete evacuation in the end, women are willing to accept some disadvantages of misoprostol to avoid curettage. A treatment inconvenience using misoprostol is accepted as long as initial evacuation rate is high. This finding should be an integral part of counselling women when deciding upon management of early pregnancy failure.
- 14 April 2005
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 20 (8) , 2340-2347
Open AccessMisoprostol versus curettage in women with early pregnancy failure: impact on women's health-related quality of life. A randomized controlled trial
BACKGROUND: We aimed to compare patients' health-related quality of life after a misoprostol strategy to a curettage in women with early pregnancy failure after failed expectant management. METHODS: A multicentre randomized clinical trial was performed in The Netherlands. In all, 154 women with early pregnancy failure confirmed at ultrasonography who had been managed expectantly unsuccessfully for ≥1 week were randomly assigned to undergo either treatment with misoprostol (n=79) or curettage (n=75). The main outcome measures were health-related quality of life and satisfaction with treatment. RESULTS: In the misoprostol strategy 47% of the women needed additional curettage, as compared to 4% after curettage. In both groups, health-related quality of life was impaired most severely 2 days after treatment. In the misoprostol group, health-related quality of life was more severely impaired; after 2 days this was due to more pain and after 2 and 6 weeks this was due to a worse general health perception. Health-related quality of life was temporarily significantly more impaired in women in whom misoprostol failed as compared to women in whom misoprostol treatment was successful. In both treatment groups, an equal percentage of women (58%) would choose the same treatment in the future. In women treated with misoprostol, however, this choice depended on the initial success of misoprostol: in cases where misoprostol had caused complete evacuation, 76% of the women would opt for the same treatment, whereas only 38% of women who needed curettage after unsuccessful misoprostol would do so (P<0.01). CONCLUSION: Our study shows that, although both the misoprostol strategy and the curettage strategy resulted in complete evacuation in the end, women are willing to accept some disadvantages of misoprostol to avoid curettage. A treatment inconvenience using misoprostol is accepted as long as initial evacuation rate is high. This finding should be an integral part of counselling women when deciding upon management of early pregnancy failure.
- Open Access
- 1 April 2005
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 20 (4) , 1067-1071
Economic evaluation of misoprostol in the treatment of early pregnancy failure compared to curettage after an expectant management
BACKGROUND: The increased pressure on health care expenses implies that physicians should consider economic aspects as part of the clinical decision-making process. Direct and indirect costs of a strategy starting with misoprostol in treatment of early pregnancy failure as compared to curettage is therefore performed. METHODS: We performed a cost-minimization analysis alongside a multicentre randomized trial. Clinical data and data on the use of medical resources were obtained from a randomized trial comparing misoprostol and curettage, which had shown that misoprostol reduced the need for curettage in 53%. In a sensitivity analysis the percentage of women who needed curettage after misoprostol varied between 25 and 90%. RESULTS: Direct costs per case were significantly lower in the misoprostol group (mean €433) than in the curettage group (mean €683) (mean difference €250, 95% CI 184 to 316, PP=0.51). The mean total costs for a strategy starting with misoprostol was €915 versus €1107 for curettage, with a mean difference between both groups of €192 (95% CI 33 to 351, P=0.04). An increase of the complete evacuation rates for initial misoprostol therapy to 90% in the sensitivity analysis increased the cost difference between misoprostol and curettage to €550. CONCLUSION: The use of misoprostol for early pregnancy failure after failed expectant management is less costly than curettage.
- 1 April 2005
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 20 (4) , 1067-1071
Open AccessEconomic evaluation of misoprostol in the treatment of early pregnancy failure compared to curettage after an expectant management
BACKGROUND: The increased pressure on health care expenses implies that physicians should consider economic aspects as part of the clinical decision-making process. Direct and indirect costs of a strategy starting with misoprostol in treatment of early pregnancy failure as compared to curettage is therefore performed. METHODS: We performed a cost-minimization analysis alongside a multicentre randomized trial. Clinical data and data on the use of medical resources were obtained from a randomized trial comparing misoprostol and curettage, which had shown that misoprostol reduced the need for curettage in 53%. In a sensitivity analysis the percentage of women who needed curettage after misoprostol varied between 25 and 90%. RESULTS: Direct costs per case were significantly lower in the misoprostol group (mean €433) than in the curettage group (mean €683) (mean difference €250, 95% CI 184 to 316, PP=0.51). The mean total costs for a strategy starting with misoprostol was €915 versus €1107 for curettage, with a mean difference between both groups of €192 (95% CI 33 to 351, P=0.04). An increase of the complete evacuation rates for initial misoprostol therapy to 90% in the sensitivity analysis increased the cost difference between misoprostol and curettage to €550. CONCLUSION: The use of misoprostol for early pregnancy failure after failed expectant management is less costly than curettage.
- 19 June 2004
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 86 (3) , 337-346
Management of early pregnancy loss
Objectives: In order to assess the available evidence on the management of early pregnancy loss, we performed a meta‐analysis on the subject. Methods: MEDLINE and EMBASE were searched for randomized studies reporting on the effectiveness of expectant management, misoprostol treatment or curettage. Outcomes considered were ‘complete evacuation’, complications, duration of bleeding, pain resulting from the procedure, side effects and women's satisfaction with the procedure. Results: Thirteen studies were identified. Combined data in women with missed abortion managed expectantly or treated with misoprostol showed complete evacuation rates of 28% (49/173) (range 14–47%) and 81% (242/298) (range 60–83%), respectively. In women with incomplete abortion, these rates were 94% (31/33) (range 80–100%) and 99% (75/76) (range 99–100%), respectively. Conclusion: In the management of early pregnancy loss both expectant management and misoprostol treatment reduce the need for curettage, but misoprostol treatment seems to be more effective in women with missed abortion as compared to expectant management.
- 19 June 2004
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 86 (3) , 337-346
Management of early pregnancy loss
Objectives: In order to assess the available evidence on the management of early pregnancy loss, we performed a meta‐analysis on the subject. Methods: MEDLINE and EMBASE were searched for randomized studies reporting on the effectiveness of expectant management, misoprostol treatment or curettage. Outcomes considered were ‘complete evacuation’, complications, duration of bleeding, pain resulting from the procedure, side effects and women's satisfaction with the procedure. Results: Thirteen studies were identified. Combined data in women with missed abortion managed expectantly or treated with misoprostol showed complete evacuation rates of 28% (49/173) (range 14–47%) and 81% (242/298) (range 60–83%), respectively. In women with incomplete abortion, these rates were 94% (31/33) (range 80–100%) and 99% (75/76) (range 99–100%), respectively. Conclusion: In the management of early pregnancy loss both expectant management and misoprostol treatment reduce the need for curettage, but misoprostol treatment seems to be more effective in women with missed abortion as compared to expectant management.
- 3 June 2004
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 19 (8) , 1894-1899
Misoprostol versus curettage in women with early pregnancy failure after initial expectant management: a randomized trial
Little is known about the effectiveness of misoprostol treatment in women with early pregnancy failure who have been managed expectantly. We therefore performed a randomized trial on this subject. Women with early pregnancy failure, who had been managed expectantly for at least 1 week, were assigned randomly (using a computer-generated list) to receive either vaginal misoprostol 800 microg or curettage. If, after 24 h, there had not been complete evacuation, a further 800 microg of misoprostol was administered. In the absence of complete evacuation after > days, curettage was performed. The primary end-point was the complete evacuation of the products of conception, with secondary end-points being the occurrence of side effects, pain intensity, need for analgesics, and intensity and duration of bleeding. In the misoprostol group, 47% (37/79) required curettage due to incomplete evacuation. After 1 week, evacuation was complete in 85% (67 out of 79) of the misoprostol group and 93% (70 out of 75) of the curettage group. Severity of pain, bleeding and emergency evacuation was higher in the misoprostol group. The complication rate was 0% for misoprostol and 4% for curettage. Curettage is superior to misoprostol in the evacuation of early pregnancy failure after failed expectant management. However, misoprostol could be clinically useful since it reduces the need for curettage by half and has a lower complication rate, at the expense of increased pain, vaginal bleeding and emergency evacuation.
- 3 June 2004
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 19 (8) , 1894-1899
Misoprostol versus curettage in women with early pregnancy failure after initial expectant management: a randomized trial
Little is known about the effectiveness of misoprostol treatment in women with early pregnancy failure who have been managed expectantly. We therefore performed a randomized trial on this subject. Women with early pregnancy failure, who had been managed expectantly for at least 1 week, were assigned randomly (using a computer-generated list) to receive either vaginal misoprostol 800 microg or curettage. If, after 24 h, there had not been complete evacuation, a further 800 microg of misoprostol was administered. In the absence of complete evacuation after > days, curettage was performed. The primary end-point was the complete evacuation of the products of conception, with secondary end-points being the occurrence of side effects, pain intensity, need for analgesics, and intensity and duration of bleeding. In the misoprostol group, 47% (37/79) required curettage due to incomplete evacuation. After 1 week, evacuation was complete in 85% (67 out of 79) of the misoprostol group and 93% (70 out of 75) of the curettage group. Severity of pain, bleeding and emergency evacuation was higher in the misoprostol group. The complication rate was 0% for misoprostol and 4% for curettage. Curettage is superior to misoprostol in the evacuation of early pregnancy failure after failed expectant management. However, misoprostol could be clinically useful since it reduces the need for curettage by half and has a lower complication rate, at the expense of increased pain, vaginal bleeding and emergency evacuation.